Google Glass video developer raises $5.4M; DARPA calls for innovative imaging proposals;

@FierceMedDev: ICYMI yesterday: Activist investor intensifies pressure on Volcano. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Interesting tidbit about off-label use: biliary stents have been used for cardiac indications in the past, panelists say. | Follow @VarunSaxena2

@EmilyWFierce: Closed-loop epidural stimulation system helped paralyzed rats take 1,000 steps and navigate "rodent-sized stairs." More from MIT Technology Review | Follow @EmilyWFierce

> Google Glass-affiliate Pristine, which develops HIPAA-compliant video streaming, raised $5.4 million in a Series A financing to use towards expansion of its R&D, sales, marketing, and operations teams. Release

> Acutus Medical, developers of the minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system, raised an additional $26.2 million in Series B financing. Release

> DARPA called for research proposals that offer innovative designs for a portable unit able to generate both neutrons and X-rays in order to maximize the imaging sources and enable more detailed radiography in field settings. Release

> Cohealo, a software development company aimed at helping hospitals manage shared medical device inventory, raised $3.1 million toward its $5.8 million debt financing goal. Story

Biotech News

@FierceBiotech: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). Article | Follow @JohnCFierce

@DamianFierce: buying antiviral outfit Alios for $1.75B in cash(!). Press release | Follow @DamianFierce

@EmilyMFierce: New class of antibiotics could fight drug-resistant tuberculosis. FierceBiotech Research story | Follow @EmilyMFierce

> Takeda steps up with $1.6B package of milestones in MacroGenics R&D pact. More

> Regeneron's would-be blockbuster completes the allergic circle with Phase II success. Article

> J&J makes a splash in hep C with a $1.75B deal for Alios. News

Pharma News

@FiercePharma: ICYMI: This week's issue of FierceAnimalHealth. Subscribe here to get it every week. | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. Story from FierceBiotech | Follow @TracyStaton

@CarlyHFierce: Once-rejected drugs in Gilead's Stribild get FDA nod to go it alone. Story | Follow @CarlyHFierce

> Salix's Relistor has its chance to get a jump on AZ's new constipation med. Report

> Allergan's next tug-of-war move: Attack Valeant's rosy Q3 forecast. Story

> AbbVie to employees: We're definitely merging with Shire, new tax rules aside. More

Biotech Research News

> New class of antibiotics could fight drug-resistant tuberculosis. More

> Protein 'map' points way to combating chemo-resistant cancer. Report

> Scientists replicate ALS dementia in mice. Item

> Hemispherx to test FDA-rejected drug, other candidates against Ebola. Article

> Monkey study reveals clues for HIV eradication. Story

Pharma Manufacturing News

> Report: Indian government to take legal action over drug quality paper. Item

> Apotex tries to 'set the record straight' after Health Canada quarantine request. More

> FDA warns of contaminated Chinese meds after toddler suffers lead poisoning. Article

> Strides and Shasun plan merger to create big, 'de-risking' production network. Story

> Credit Suisse: FDA 483 unlikely to lead to import alert for Sun. Report

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.